pharmaphorum

FEBRUARY 9, 2021

In the final instalment of our series reviewing the t he 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), Leela Barham takes stock of the whole scheme after digging more deeply into its three objectives. There is an opportunity however, in the next three years, to bring clarity in how the VPAS is assessed.

Life Science 86

Life Science Branding Medicine Sales 86

pharmaphorum

FEBRUARY 16, 2022

Leela Barham and Neil Grubert look back at what was expected for market access in 2021 and look ahead at what 2022 could hold. Will all the efforts to speed up market access and ensure that the UK remains attractive to the life sciences industry post-Brexit pay off in 2022? Close to 60 percent (41) were successful.

Marketing 52

Marketing Life Science Medicine Gene Therapy 52

The Pharma Data

MAY 4, 2021

Following the completion of the spin-off of the Upjohn Business (4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. previously $59.4 previously 32.0%

Vaccination 40

Vaccination Vaccine Production Sales 40